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Blood vessels supply all body tissues with nutrients and oxygen, take away waste
products and allow the arrival of immune cells and other cells (pericytes, smooth muscle
cells) that form part of these vessels around the principal endothelial cells. Vasculogenic
mimicry (VM) is a tumor blood supply system that takes place independently of
angiogenesis or endothelial cells, and is associated with poor survival in cancer patients.
Aberrant expression of VE-cadherin has been strongly associated with VM. Even more,
VE-cadherin has constitutively high phosphorylation levels on the residue of Y658 in
humanmalignant melanoma cells. In this reviewwe focus on non-endothelial VE-cadherin
and its post-translational modifications as a crucial component in the development of
tumor VM, highlighting the signaling pathways that lead to their pseudo-endothelial
and stem-like phenotype and the role of tumor microenvironment. We discuss the
importance of the tumor microenvironment in VM acquisition, and describe the most
recent therapeutic targets that have been proposed for the repression of VM.
Keywords: vasculogenic mimicry, tumor microenvironment, metastasis, VE-cadherin, anti-angiogenesis
therapeutic failure, cell plasticity
BACKGROUND
The concept of neovascularization was described for the first time in 1787 in the context of
developmental biology. The term angiogenesis was coined early in the 20th century but was not
applied to tumor biology until decades later (1). Angiogenesis can arise in a variety of forms during
cancer, namely sprouting angiogenesis, intussusceptive microvascular growth, and glomeruloid
microvascular proliferation (2). Emerging studies have shown that a few tumors can grow without
need of angiogenesis even in hypoxic conditions, while other tumors display both angiogenic and
non-angiogenic regions (3). Vasculogenic mimicry refers to the ability of cancer cells to organize
themselves into vascular-like structures for the obtention of nutrients and oxygen independently of
normal blood vessels or angiogenesis.
Research in VM has often been surrounded by skepticism to a certain extent. The reason for this
controversy is usually the difficulty to distinguish VM channels from endothelial blood vessels or
blood lakes in vivo. Similarly, in vitro research presents inherent inconveniences, given the need to
develop 3-D models where tumor cells can develop capillary-like structures. Most in vitro research
is based on cell cultures using matrigel. However, the tubular structures observed in this model
might not always represent in vivo VM. Table 1 shows a few articles where VM is thoroughly
described in various cancer types in vivo and in vitro (4–10, 12, 13).
The unique arrangement of VM grids simulates embryonic vasculogenesis, suggesting that
malignant tumor cells acquire an embryonic-like phenotype. Gene expression analysis showed
that aggressive tumor cells capable of VM display a diversified gene profile, expressing genes from
multiple cell types such as epithelial cells, fibroblasts and endothelial cells (16, 17). Nevertheless,
the molecular mechanisms that give rise to VM remain largely unknown.
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TABLE 1 | Main tumor types where VM has been reported and main inhibitors described against VM.
Cancer type In vitro (Molecular target involved) In vivo (Molecular target involved)
Tumor types presenting VM
Breast Liu et al. (4) (S1PR1/VE-cadherin) Liu et al. (5) (CD133,MMP-2/9), Liu et al. (4)
(S1PR1/VE-cadherin)
Colon Qi et al. (6) (Wnt 3a, β-catenin, VEGFR1/2,
VE-cadherin)
Qi et al. (6) (Wnt 3a, β-catenin, VEGFR1/2,
VE-cadherin)
Glioblastoma multiforme El Hallani et al. (7) (EphA2, laminin 5γ2, TFPI-1,
Neuropilin-2, endoglin)
Hepatocellular carcinoma Sun et al. (8) (Twist-1, VE-cadherin, MMP-9)
Lung cancer Xia et al. (9) (Sema4D, MMP-2/9, VE-cadherin,
EphA2, PlexinB1)
Melanoma Dunleavey et al. (10) (CD31, tyrosinase, AP-2α)
Pancreas Yang et al. (11) (HIF-2α, VE-cadherin, Twist1) Yang et al. (11) (HIF-2α, VE-cadherin, Twist1)
Ovarian Racordon et al. (12) Tang et al. (13) (Urokinase, MMP-2, AKT)
Small cell lung Williamson et al. (14) (VE-cadherin) Williamson et al. (14) (VE-cadherin)
Ewing sarcoma van der Schaft et al. (15) (TFPI-1,
VE-cadherin, Integrin α3, EphA2)
van der Schaft et al. (15) (TFPI-1, VE-cadherin,
Integrin α3, EphA2)
Novel therapeutic agents Molecular target or function Effect on VM
Targeting VM
CMV-1118 Phospho-MAPK/phospho-kinases, cell stress
checkpoints, and apoptosis regulators
Inhibition in vitro, phase I clinical trials with sorafenib
(NCT03582618)
PF-562271 FAK Inhibition in vitro
AKB-9978 VE-PTP/TIE-2 No data
STI-571 PDGF-β Inhibition in vitro and in vivo
Vascular endothelial cadherin (VE-cadherin), also known as
cadherin 5 or CD144, is a cell-cell adhesion protein commonly
expressed by endothelial cells. Phosphorylation of VE-cadherin
at a number of residues can modulate endothelial junction
stability and permeability in different contexts (18). VE-cadherin
was believed to be specific for endothelial cells (ECs), though
in the past few decades it has been found in a wide variety of
tumors, where it crucially contributed to aggressiveness and VM.
In fact, VE-cadherin was found in highly aggressive tumor cells
but it was not expressed by their poorly aggressive counterparts.
Moreover, VE-cadherin down-regulation leads to the inhibition
of VM formation (19). In this mini-review, we focus on the new
findings on the role of extravascular VE-cadherin and its different
localizations in the acquisition of the VM phenotype. In addition,
we discuss the influence of the tumor microenvironment,
stromal cells and mural cells in the development
of VM.
VE-CADHERIN IN NON-ENDOTHELIAL
CONTEXT
VE-cadherin is a single pass transmembrane protein typically
found in endothelium, where it takes part in adherents junctions
(20). VE-cadherin has been extensively studied with reference
to vascular adhesion, but its function during VM in aggressive
tumor cells is not fully understood. The structure of VE-
cadherin contains five extracellular calcium-dependent domains
(aminoacid residues 46-599) which can establish cis homodimers
with another VE-cadherin molecule. Similarly, VE-cadherin can
form trans dimers binding through the ECDI-ECDIV domains.
The intracellular domain of VE-cadherin can undergo several
post-translational modifications and 13 different residues of
VE-cadherin have been reported to undergo phosphorylation
in humans. Of these, residues Y658, S665, Y685, and Y731
have drawn most of the attention. They have been implicated
in the intracellular dynamics of the cytoskeleton that control
endothelial permeability. In particular, phosphorylation of
VE-cadherin can trigger junctional changes via VE-cadherin
internalization. As a result, vascular permeability is increased,
allowing intravasation and extravasation of different cell types,
including tumor cells (21). Recent investigations demonstrated
that focal adhesion kinase (FAK) can phosphorylate VE-cadherin
at Y658 in tumor-associated ECs, pinpointing the importance
of FAK in regulating EC barrier function and hence tumor
metastasis (22). FAK is a cytoplasmic tyrosine kinase co-activated
by vascular endothelial growth factor receptor (VEGFR) 2 and
integrin in the control of vascular permeability (23). Recently,
we reported that human aggressive melanoma cells have a
constitutively high FAK-dependent phosphorylation of VE-
cadherin at Y658 (pY658-VEC). pY658-VEC interacts with p120-
catenin and the transcriptional repressor kaiso in the nucleus.
The inhibition of FAK led to the release of kaiso, promoting
its recruitment to kaiso binding sites and therefore repressing
kaiso target genes. Moreover, the repression of kaiso target
genes CCDN1 and WNT11 abrogated VM. In that line, uveal
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FIGURE 1 | Main signaling pathways implicated in VE-cadherin/VM-positive cells. VE-cadherin can be phosphorylated by VEGFR-2, alone or in a NRP-1-dependent
manner, in response to different VEGF soluble factors. These stimuli lead to the phosphorylation of VE-cadherin at Y658 and its subsequent internalization.
pY658-VEC can interact with p120 and Kaiso. This complex prevents Kaiso from binding its target genes (CCND1, WNT11), promoting VM formation in aggressive
melanoma models. VE-PTP may be an important factor in the maintenance of VE-cadherin phosphorylation status, and catenins p120 or β-catenin may influence the
VE-PTP/VE-cadherin axis. On the other hand, VM-positive aggressive melanoma cells showed an up-regulation in a number of proteins, as compared with poorly
melanoma cells. One of these proteins was TIE-1, which may be a target of VE-PTP, suggesting an implication in the TIE/angiopoietin pathway.
melanoma cells genetically deficient for VE-cadherin (either
through CRISPR/Cas9 technology or after silencing of VE-
cadherin) lost the ability to develop VM. Even more, the
rescue of WT-VE-cadherin reverted the ability to form VM;
in contrast, expression of the non-phosphorylated Y658F-VE-
cadherin blunted in vitro VM (24) (see Figure 1).
The intracellular domain V of VE-cadherin is necessary to
bind vascular endothelial protein tyrosine phosphatase (VE-
PTP) (25), in a plakoglobin (γ-catenin)-dependent way (26,
27). VE-PTP is an endothelial receptor-type phosphatase which
was first described in relation to its implications in embryonic
vasculature. VE-PTP-deficient mice undergo vasculogenesis but
still die at the embryonic stage due to angiogenesis malfunction
(28). VE-PTP may have many other implications, such as ocular
vascular pathology (29), blood vessels development (30), breast
cancer vasculature and metastatic progression (31). VE-PTP is
also involved with the TIE1/2-Angiopoietin pathway. Different
laboratories have shown that targeting VE-PTP with a specific
inhibitor (AKB-9978, Aerpio Pharmaceuticals) activates TIE2
and stabilizes the ocular vasculature in ischemic/inflammation
models (29). AKB-9778 induced TIE2 phosphorylation, directly
as well as viaANG1. Furthermore, other signaling components of
the TIE2 pathway, such as ERK, AKT, and eNOS (see Figure 1),
also display increased phosphorylation (29). In 2015, Gong
et al. reported that hypoxia increased the expression of VE-
PTP in acute lung injury in a HIF-2α-dependent manner (32).
All of these functions of VE-PTP have always been studied
in endothelial models, though the implications of the VE-
PTP/VE-cadherin axis in a VM context remain unknown. In
view of the anomalously high levels of phospho-VE-cadherin
in cells undergoing VM and the role of VE-PTP in the
exquisite maintenance of VE-cadherin phosphorylation, new
studies should address the function of this phosphatase in
regulating vasculogenic mimicry.
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TUMOR MICROENVIRONMENT AND VM
The complexity of tumors has been increasingly acknowledged in
the past decades, to the point where numerous articles published
in the cancer research field are no longer focused exclusively on
cancer cells. On the contrary, the different components of the
tumor microenvironment have received ever greater attention.
Low oxygen concentration in tumors, commonly known as
tumor hypoxia, has been repeatedly associated with malignancy,
metastasis and therapy resistance in cancer (33). Hypoxia has
been linked to VM by many research groups as well (15).
In hepatocellular carcinoma, hypoxia promoted VM through
transcriptional co-activation of Bcl-2 and Twist1 (34). Nuclear
co-expression of Bcl2 and Twist1 correlated with VE-cadherin
expression in tumor cells. In fact, VE-cadherin gene expression
can be induced by hypoxia, specifically by hypoxia inducible
factor (HIF) 2α (35). Though it was first described in ECs,
hypoxia-driven expression of VE-cadherin has been reported in
a large number of tumor types too (36–38), where it is always
involved in a promotion of the VM phenotype.
Hypoxia has been shown to promote VM through other
signaling pathways apart from VE-cadherin. For instance,
reactive oxygen species (ROS)-mediated stabilization of HIF1α
activated the met proto-oncogene, which induced in vitro tube
formation on matrigel in melanoma cells (39). Moreover, HIF1-
andHIF2α promoted in vitro tube formation onmatrigel through
the upregulation of vascular endothelial growth factors (VEGF)
C and D, as well as VEGF receptor (VEGFR)3 (40). In triple
negative breast cancer, hypoxia increased the subpopulation of
CD133+ cells (commonly regarded as cancer stem cells) through
a Twist1-mediated mechanism. This population shift seemed to
enhance tube formation, since CD133+ cells were found to line
the VM-like tubes (41). In addition, HIF1α could promote tube
formation in hepatocellular carcinoma by up-regulating lysyl
oxidase like 2 (LOXL2) (42, 43), which is involved in collagen
cross-linkage during extracellular matrix (ECM) remodeling.
ECM per se can play a fundamental role in regulating
VM. The NC11 domain in collagen XVI could trigger tube
formation in oral squamous cell carcinoma, since it could induce
VEGFR1/2 expression (43). On the contrary, the presence of
collagen I altered the vascular potential of pancreatic ductal
adenocarcinoma (PDAC) CSCs, decreasing the secretion of pro-
angiogenic factors and the expression of VEGFR2, altogether
hindering VM formation in PDAC (44). Furthermore, Velez et al.
showed that ECM architecture can influence VM; in particular,
collagen matrices with small pores and short fibers induced
β-integrin expression and hence VM (45).
The importance of non-cancer cells within the tumor stromal
is slowly gaining attention in the study of VM as well.
Tumor-associated macrophages (TAMs) seemed to promote
VM formation in glioblastoma multiforme, namely increasing
the expression of cyclooxygenase 2 in the tumor cells (46).
Cancer-associated fibroblasts (CAFs) can be determinant in VM
formation too. In a recent study, vasculogenic murine melanoma
cells were injected in mice carrying a CAF-specific deletion for
the matricellular protein CCN2. As a result, the absence of
fibroblast-derived CCN2 reduced tumor vasculature, including
VM (47). Finally, a recent publication by Thijssen et al. (48)
showed that PAS+ tissues in human cutaneousmelanoma stained
positive for pericyte marker α-smooth muscle actin (αSMA)
within the ECM networks lined by tumor cells. Furthermore,
when VM+ tumor cells were co-cultured with pericytes, there
was a stabilization of the VM networks for up to 96 h. Pericyte
recruitment to VM networks was shown to be dependent on
PDBF-B signaling, whereas the addition of STI-571 (imatinib
mesylate) to inhibit PDGF receptor hindered VM as well as
tumor growth.
TARGETING VM AND PERSPECTIVES
A meta-analysis of 22 clinical studies derived from data
concerning VM and 5-year survival of 3,062 patients across 15
cancer types showed that tumor VM is correlated with poor
prognosis (49). Anti-angiogenic therapies (preferably, antibodies
against VEGF receptor bevacizumab and related) against
tumor development have had limited results so far. Therefore,
the development of novel anti-tumor neovascularization
strategies is of vital importance, expanding the targets from
conventional angiogenesis to all the alternative mechanisms
recently discovered, such as VM (50).
A unique small molecular compound with particular
interest in anti-VM cancer treatment is CVM-1118, which is
currently undergoing clinical trials (NCT03582618). CVM-
1118 is classified as a phenyl-quinoline derivative, whose core
structure displays potent anti-neoplastic and anti-mutagenic
properties (51).
As mentioned above, pharmacological inhibition of activity
of FAK/Y658 VE-cadherin with PF-271 may represent a new
therapeutic opportunity in the repression of genes involved
with VM promotion in cancer cells. Similarly, inhibition of
the VE-PTP/TIE-2 pathway with AKB-9778 could open new
ways to control the capacity to form pseudo-vessels by vascular
mimicry cells. Finally, new treatments targeting mural cells, such
as pericytes, could also have therapeutic value. It is the case
of targeting PDGF-B axis with STI-571, which proved useful
in VM mice models. Targeting VM with specific molecular
compounds combined with front-line therapies may represent
the best approach to obtain a good prognosis in patients in
the future.
AUTHOR CONTRIBUTIONS
MF-C and DD-B designed and wrote the review. FO designed,
wrote and coordinated the review.
FUNDING
This work was supported by the grants from the Spanish
Ministry of Economy and Competitiveness SAF2015-70520-R,
Fundación Domingo Martínez and the Spanish Ministry of
Science and Technology RTI2018-098968-B-I00 and CIBERONC
ISCIII CB16/12/00421 to FO.
Frontiers in Oncology | www.frontiersin.org 4 August 2019 | Volume 9 | Article 803
Fernández-Cortés et al. Pseudo-endothelial Phenotype of Tumor Cells
REFERENCES
1. Natale G, Bocci G, Lenzi P. Looking for the word “Angiogenesis” in the history
of health sciences: from ancient times to the first decades of the twentieth
century.World J Surg. (2017) 41:1625–34. doi: 10.1007/s00268-016-3680-1
2. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization
mechanisms in cancer: pathology and therapeutic implications. Am J Pathol.
(2007) 170:1–15. doi: 10.2353/ajpath.2007.060302
3. Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E,
et al. Vessel co-option is common in human lung metastases and mediates
resistance to anti-angiogenic therapy in preclinical lung metastasis models. J
Pathol. (2017) 241:362–74. doi: 10.1002/path.4845
4. Liu S, Ni C, Zhang D, Sun H, Dong X, Che N, et al. S1PR1 regulates the switch
of two angiogenic modes by VE-cadherin phosphorylation in breast cancer.
Cell Death Dis. (2019) 10:200. doi: 10.1038/s41419-019-1411-x
5. Liu TJ, Sun BC, Zhao XL, Zhao XM, Sun T, Gu Q, et al. CD133+ cells with
cancer stem cell characteristics associates with vasculogenic mimicry in triple-
negative breast cancer. Oncogene. (2013) 32:544–53. doi: 10.1038/onc.2012.85
6. Qi L, SongW, Liu Z, Zhao X, CaoW, Sun B.Wnt3a promotes the vasculogenic
mimicry formation of colon cancer via Wnt/beta-catenin signaling. Int J Mol
Sci. (2015) 16:18564–79. doi: 10.3390/ijms160818564
7. El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, et al. A new
alternative mechanism in glioblastoma vascularization: tubular vasculogenic
mimicry. Brain. (2010) 133:973–82. doi: 10.1093/brain/awq044
8. Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, et al. Expression and
functional significance of Twist1 in hepatocellular carcinoma: its role in
vasculogenic mimicry. Hepatology. (2010) 51:545–56. doi: 10.1002/hep.23311
9. Xia Y, Cai XY, Fan JQ, Zhang LL, Ren JH, Li ZY, et al. The role
of sema4D in vasculogenic mimicry formation in non-small cell lung
cancer and the underlying mechanisms. Int J Cancer. (2019) 144:2227–38.
doi: 10.1002/ijc.31958
10. Dunleavey JM, Xiao L, Thompson J, Kim MM, Shields JM, Shelton SE, et al.
Vascular channels formed by subpopulations of PECAM1+ melanoma cells.
Nat Commun. (2014) 5:5200. doi: 10.1038/ncomms6200
11. Yang J, Zhu D-M, Zhou X-G, Yin N, Zhang Y, Zhang Z-X, et al. HIF-2α
promotes the formation of vasculogenic mimicry in pancreatic cancer by
regulating the binding of Twist1 to the VE-cadherin promoter. Oncotarget.
(2017) 8:47801–15. doi: 10.18632/oncotarget.17999
12. Racordon D, Valdivia A, Mingo G, Erices R, Aravena R, Santoro F, et al.
Structural and functional identification of vasculogenic mimicry in vitro. Sci
Rep. (2017) 7:6985. doi: 10.1038/s41598-017-07622-w
13. Tang J, Wang J, Fan L, Li X, Liu N, Luo W, et al. cRGD inhibits vasculogenic
mimicry formation by down-regulating uPA expression and reducing EMT in
ovarian cancer,Oncotarget. (2016) 7:24050–62. doi: 10.18632/oncotarget.8079
14. Williamson SC, Metcalf RL, Trapani F, Mohan S, Antonello J, Abbott B, et al.
Vasculogenic mimicry in small cell lung cancer.Nat Commun. (2016) 7:13322.
doi: 10.1038/ncomms13322
15. van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K,
Egbrink MG, et al. Tumor cell plasticity in Ewing sarcoma, an alternative
circulatory system stimulated by hypoxia. Cancer Res. (2005) 65:11520–8.
doi: 10.1158/0008-5472.CAN-05-2468
16. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular
classification of cutaneous malignant melanoma by gene expression profiling.
Nature. (2000) 406:536–40. doi: 10.1038/35020115
17. Seftor EA, Meltzer PS, Kirschmann DA, Pe’er J, Maniotis AJ, Trent JM, et al.
Molecular determinants of human uveal melanoma invasion and metastasis.
Clin Exp Metastasis. (2002) 19:233–46. doi: 10.1023/A:1015591624171
18. Breier G, Grosser M, Rezaei M. Endothelial cadherins in cancer. Cell Tissue
Res. (2014) 355:523–7. doi: 10.1007/s00441-014-1851-7
19. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA,
et al. Expression and functional significance of VE-cadherin in aggressive
humanmelanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA.
(2001) 98:8018–23. doi: 10.1073/pnas.131209798
20. Giannotta M, Trani M, Dejana E. VE-cadherin and endothelial
adherens junctions: active guardians of vascular integrity.
Dev Cell. (2013) 26:441–54. doi: 10.1016/j.devcel.2013.
08.020
21. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions
and VE-cadherin in the control of vascular permeability. J Cell Sci. (2008)
121:2115–22. doi: 10.1242/jcs.017897
22. Jean C, Chen XL, Nam JO, Tancioni I, Uryu S, Lawson C, et al. Inhibition
of endothelial FAK activity prevents tumor metastasis by enhancing barrier
function. J Cell Biol. (2014) 204:247–63. doi: 10.1083/jcb.201307067
23. Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, et al. VEGF-
induced vascular permeability is mediated by FAK. Dev Cell. (2012) 22:146–
57. doi: 10.1016/j.devcel.2011.11.002
24. Delgado-Bellido D, Fernandez-Cortes M, Rodriguez MI, Serrano-Saenz S,
Carracedo A, Garcia-Diaz A, et al. VE-cadherin promotes vasculogenic
mimicry by modulating kaiso-dependent gene expression. Cell Death Differ.
(2018) 26:348–61. doi: 10.1038/s41418-018-0125-4
25. Nawroth R, Poell G, Ranft A, Kloep S, Samulowitz U, Fachinger
G, et al. VE-PTP and VE-cadherin ectodomains interact to facilitate
regulation of phosphorylation and cell contacts. EMBO J. (2002) 21:4885–95.
doi: 10.1093/emboj/cdf497
26. Muramatsu F, Kidoya H, Naito H, Hayashi Y, Iba T, Takakura N. Plakoglobin
maintains the integrity of vascular endothelial cell junctions and regulates
VEGF-induced phosphorylation of VE-cadherin. J Biochem. (2017) 162:55–
62. doi: 10.1093/jb/mvx001
27. Nottebaum AF, Cagna G, Winderlich M, Gamp AC, Linnepe R, Polaschegg C,
et al. VE-PTP maintains the endothelial barrier via plakoglobin and becomes
dissociated from VE-cadherin by leukocytes and by VEGF. J Exp Med. (2008)
205:2929–45. doi: 10.1084/jem.20080406
28. Dominguez MG, Hughes VC, Pan L, Simmons M, Daly C, Anderson K,
et al. Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo
vasculogenesis but die embryonically because of defects in angiogenesis.
Proc Natl Acad Sci USA. (2007) 104:3243–8. doi: 10.1073/pnas.061151
0104
29. Shen J, FryeM, Lee BL, Reinardy JL, McClung JM, Ding K, et al. Targeting VE-
PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. (2014)
124:4564–76. doi: 10.1172/JCI74527
30. Baumer S, Keller L, Holtmann A, Funke R, August B, Gamp A, et al.
Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP)
activity is required for blood vessel development. Blood. (2006) 107:4754–62.
doi: 10.1182/blood-2006-01-0141
31. Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Kirkpatrick ND, et al.
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on
breast cancer vasculature and metastatic progression. J Natl Cancer Inst.
(2013) 105:1188–201. doi: 10.1093/jnci/djt164
32. Gong H, Rehman J, Tang H, Wary K, Mittal M, Chaturvedi P, et al. HIF2alpha
signaling inhibits adherens junctional disruption in acute lung injury. J Clin
Invest. (2015) 125:652–64. doi: 10.1172/JCI77701
33. Nobre AR, Entenberg D,Wang Y, Condeelis J, Aguirre-Ghiso JA. The different
routes to metastasis via hypoxia-regulated programs. Trends Cell Biol. (2018)
28:941–56. doi: 10.1016/j.tcb.2018.06.008
34. Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X. Hypoxia
influences vasculogenic mimicry channel formation and tumor invasion-
related protein expression in melanoma. Cancer Lett. (2007) 249:188–97.
doi: 10.1016/j.canlet.2006.08.016
35. Le Bras A, Lionneton F, Mattot V, Lelievre E, Caetano B, Spruyt N, et al.
HIF-2alpha specifically activates the VE-cadherin promoter independently of
hypoxia and in synergy with Ets-1 through two essential ETS-binding sites.
Oncogene. (2007) 26:7480–9. doi: 10.1038/sj.onc.1210566
36. Mao XG, Xue XY, Wang L, Zhang X, Yan M, Tu YY, et al. CDH5
is specifically activated in glioblastoma stemlike cells and contributes to
vasculogenic mimicry induced by hypoxia. Neuro Oncol. (2013) 15:865–79.
doi: 10.1093/neuonc/not029
37. Du J, Sun B, Zhao X, Gu Q, Dong X, Mo J, et al. Hypoxia promotes
vasculogenic mimicry formation by inducing epithelial-mesenchymal
transition in ovarian carcinoma. Gynecol Oncol. (2014) 133:575–83.
doi: 10.1016/j.ygyno.2014.02.034
38. Tang N-N, Zhu H, Zhang H-J, Zhang W-F, Jin H-L, Wang L, et al. HIF-
1α induces VE-cadherin expression and modulates vasculogenic mimicry
in esophageal carcinoma cells. World J Gastroenterol. (2014) 20:17894.
doi: 10.3748/wjg.v20.i47.17894
Frontiers in Oncology | www.frontiersin.org 5 August 2019 | Volume 9 | Article 803
Fernández-Cortés et al. Pseudo-endothelial Phenotype of Tumor Cells
39. Comito G, Calvani M, Giannoni E, Bianchini F, Calorini L, Torre E,
et al. HIF-1alpha stabilization by mitochondrial ROS promotes Met-
dependent invasive growth and vasculogenic mimicry in melanoma cells.
Free Radic Biol Med. (2011) 51:893–904. doi: 10.1016/j.freeradbiomed.2011.
05.042
40. Spinella F, Caprara V, Di Castro V, Rosano L, Cianfrocca R, Natali
PG, et al. Endothelin-1 induces the transactivation of vascular
endothelial growth factor receptor-3 and modulates cell migration and
vasculogenic mimicry in melanoma cells. J Mol Med. (2013) 91:395–405.
doi: 10.1007/s00109-012-0956-2
41. Zhang Y, Sun B, Zhao X, Liu Z,Wang X, Yao X, et al. Clinical significances and
prognostic value of cancer stem-like cells markers and vasculogenic mimicry
in renal cell carcinoma. J Surg Oncol. (2013) 108:414–9. doi: 10.1002/jso.23402
42. Wang M, Zhao X, Zhu D, Liu T, Liang X, Liu F, et al. HIF-1alpha promoted
vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2
up-regulation in hypoxic tumor microenvironment. J Exp Clin Cancer Res.
(2017) 36:60. doi: 10.1186/s13046-017-0533-1
43. Bedal KB, Grassel S, Spanier G, Reichert TE, Bauer RJ. The NC11
domain of human collagen XVI induces vasculogenic mimicry in
oral squamous cell carcinoma cells. Carcinogenesis. (2015) 36:1429–39.
doi: 10.1093/carcin/bgv141
44. Biondani G, Zeeberg K, Greco MR, Cannone S, Dando I, Dalla Pozza E,
et al. Extracellular matrix composition modulates PDAC parenchymal and
stem cell plasticity and behavior through the secretome. FEBS J. (2018)
285:2104–24. doi: 10.1111/febs.14471
45. Velez DO, Tsui B, Goshia T, Chute CL, Han A, Carter H, et al. 3D
collagen architecture induces a conserved migratory and transcriptional
response linked to vasculogenic mimicry. Nat Commun. (2017) 8:1651.
doi: 10.1038/s41467-017-01556-7
46. Rong X, Huang B, Qiu S, Li X, He L, Peng Y. Tumor-associated
macrophages induce vasculogenic mimicry of glioblastoma multiforme
through cyclooxygenase-2 activation. Oncotarget. (2016) 7:83976–86.
doi: 10.18632/oncotarget.6930
47. Hutchenreuther J, Vincent K, Norley C, Racanelli M, Gruber
SB, Johnson TM, et al. Activation of cancer-associated fibroblasts
is required for tumor neovascularization in a murine model of
melanoma. Matrix Biol. (2018) 74:52–61. doi: 10.1016/j.matbio.2018.0
6.003
48. Thijssen VL, Paulis YW, Nowak-Sliwinska P, Deumelandt KL, Hosaka K,
Soetekouw PM, et al. Targeting PDGF-mediated recruitment of pericytes
blocks vascular mimicry and tumor growth. J Pathol. (2018) 246:447–58.
doi: 10.1002/path.5152
49. Cao Z, Bao M, Miele L, Sarkar FH, Wang Z, Zhou Q. Tumour vasculogenic
mimicry is associated with poor prognosis of human cancer patients:
a systemic review and meta-analysis. Eur J Cancer. (2013) 49:3914–23.
doi: 10.1016/j.ejca.2013.07.148
50. Schnegg CI, Yang MH, Ghosh SK, Hsu M-Y. Induction of
vasculogenic mimicry overrides VEGF-A silencing and enriches
stem-like cancer cells in melanoma. Cancer Res. (2015) 75:1682–90.
doi: 10.1158/0008-5472.CAN-14-1855
51. Huang MT, Wood AW, Newmark HL, Sayer JM, Yagi H, Jerina DM, et al.
Inhibition of the mutagenicity of bay-region diol-epoxides of polycyclic
aromatic hydrocarbons by phenolic plant flavonoids. Carcinogenesis. (1983)
4:1631–7. doi: 10.1093/carcin/4.12.1631
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Fernández-Cortés, Delgado-Bellido and Oliver. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Oncology | www.frontiersin.org 6 August 2019 | Volume 9 | Article 803
